Intercept (ICPT) Most Lucrative Opportunity Remains in NASH - Baird

Intercept Pharma (ICPT):Higher-Than-Anticipated Pricing Could Set the Stage for a Slow Ocaliva Launch - FBR

FBR Capital analyst, Vernon Bernardino, maintained his Market Perform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) and believes "that the upside potential and downside risk are evenly balanced" as higher-than-anticipated pricing could pose a high hurdle for gaining medical insurance (payor) coverage. PT increases to $200 (from... More

Intercept Pharmaceuticals (ICPT) PT Comes Down to $239 at Wedbush Following OCALIVA Approval

Wedbush analyst Liana Moussatos reiterated an Outperform on Intercept Pharmaceuticals (NASDAQ: ICPT) while converting to a 12-month price target of $239.00 (from acquisition value of $423.00) after the company anounced U.S. approval of obeticholic acid (OCA) as OCALIVA for primary biliary cholangitis (PBC).

While... More

Intercept (ICP) OCA Approval a 'Major De-Risking Event' - BMO

BMO Capital analyst M. Ian Somaiya reiterated an Outperform Intercept Pharmaceuticals (NASDAQ: ICPT) but trimmed its price target to $219.00 (from $221.00) following Ocaliva approval.

Somaiya commented, "We believe Ocalivas approval in primarily biliary cholangitis (PBC) is a major de-risking event for ICPT. We... More

Intercept Pharmaceuticals (ICPT) PT Trimmed to $140 at Leerink Partners

Leerink Partners analyst Joseph Schwartz reiterated an Market Perform rating and trimmed his price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $140.00 (from $144.00) after OCALIVA was approved and priced at $69K per yera. The analyst remains cautious on the speed of market uptake for... More

Needham & Company Positive on Intercept Pharma (ICPT); Expects Initial Ocaliva Uptake to be 'Strong'

Needham & Company affirms Intercept Pharma (Nasdaq: ICPT) at Buy with a price target of $350 after the company received FDA... More

Intercept Pharma (ICPT) says Ocaliva list price is $69,350/year

Intercept Pharma (NASDAQ: ICPT) says Ocaliva list price is $69,350/year

Intercept Pharma (ICPT) Granted Accelerated FDA Approval of Ocaliva in PBC

Late Friday, Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), in combination with ursodeoxycholic (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Ocaliva is an agonist of the farnesoid X receptor (FXR), a nuclear receptor expressed in the liver and intestine and a key regulator of bile acid, inflammatory, fibrotic... More